The DOI matches its Crossref record; 366 of the 371 references it cites were found in a registry or an index.
EASL Clinical Practice Guidelines: Drug-induced liver injury
Abstract
Idiosyncratic (unpredictable) drug-induced liver injury is one of the most challenging liver disorders faced by hepatologists, because of the myriad of drugs used in clinical practice, available herbs and dietary supplements with hepatotoxic potential, the ability of the condition to present with a variety of clinical and pathological phenotypes and the current absence of specific biomarkers. This makes the diagnosis of drug-induced liver injury an uncertain process, requiring a high degree of awareness of the condition and the careful exclusion of alternative aetiologies of liver disease. Idiosyncratic hepatotoxicity can be severe, leading to a particularly serious variety of acute liver failure for which no effective therapy has yet been developed. These Clinical Practice Guidelines summarize the available evidence on risk factors, diagnosis, management and risk minimization strategies for drug-induced liver jury.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Drug-induced liver injury (DILI) is an uncommon adverse reaction to drugs, and other chemicals, including herbal and dietary supplements (HDS).”
From DILI Differences and Similarities between the US and Europe (2026) · cites this paper as [2]
In the citing paper
“The vast majority of cases of DILI occur at therapeutic doses in a small proportion of individuals exposed to the drug, representing an idiosyncratic reaction, and therefore unpredictable based on the drug's mechanism of action and related to the uniqueness of the individual [1,2].”
From DILI Differences and Similarities between the US and Europe (2026) · cites this paper as [2]
In the citing paper
“In pediatric medicine, DILI is a rare clinical situation. However, it has high morbidity and mortality, and it is one of the most common causes of acute liver failure. Furthermore, its diagnosis is clinically challenging due to its low incidence and phenotypic variability [6,7,8].”
From Metabolomic Analysis of Pediatric Patients with Idiosyncratic Drug-Induced Liver Injury According to the Updated RUCAM (2023) · cites this paper as [7]
In the citing paper
“The lack of a reliable diagnostic biomarker and evidence-based treatment paradigm has resulted in limited guidance on how to manage this aspect of DILI.”
From Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report (2023) · cites this paper as [2]
In the citing paper
“The lack of reliable diagnostic biomarkers and an evidence-based treatment paradigm has resulted in limited guidance on how to manage this aspect of DILI.2,25–27”
From Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report (2023) · cites this paper as [2]
In the citing paper
“However, drug rechallenge in DILI cases is potentially dangerous2,75 and is associated with risk of death or requirement for liver transplant.”
From Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report (2023) · cites this paper as [2]
In the citing paper
“Although there are some ambiguities regarding how to score certain sections as well as suboptimal reliability, RUCAM can provide systematic and framed guidance for the assessment of patients with suspected DILI and is the most widely used tool [26,27,51,59].”
From Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update (2024) · cites this paper as [26]
In the citing paper
“High TBil and ALP levels in the second month after an acute DILI episode and the biochemical nonresolution-6 model may help predict the risk of chronic injury and delayed recovery [26,72].”
From Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update (2024) · cites this paper as [26]
In the citing paper
“Although there are some ambiguities regarding how to score certain sections as well as suboptimal reliability, RUCAM can provide systematic and framed guidance for the assessment of patients with suspected DILI and is the most widely used tool [26,27,51,59].”
From Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update (2024) · cites this paper as [26]
In the citing paper
“Its potential value in confirming or excluding hepatocellular injury in cases of elevated ALT levels from a suspected extrahepatic origin (e.g., muscle) has been evaluated [26,175].”
From Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update (2024) · cites this paper as [26]
Citations
Cites
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280
Ekor, M. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00177 · Cited by 3,919
Alvarez, F., Berg, P. A., Bianchi, F. B., Bianchi, L., Burroughs, A. K., Cancado, E. L., Chapman, R. W., Cooksley, W. G. E., Czaja, A. J., Desmet, V. J., et al. (1999) · Journal of Hepatology · doi:10.1016/s0168-8278(99)80297-9 · Cited by 2,903
The influence of drug-like concepts on decision-making in medicinal chemistry
Leeson, P. D., & Springthorpe, B. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2445 · Cited by 2,403
Haanen, J. B. A. G., Carbonnel, F., Robert, C., Kerr, K. M., Peters, S., Larkin, J., & Jordan, K. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx225 · Cited by 2,367
Ostapowicz, G., Fontana, R. J., Schiødt, F. V., Larson, A., Davern, T. J., Han, S. H. B., McCashland, T. M., Shakil, A. O., Hay, J. E., Hynan, L., et al. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-12-200212170-00007 · Cited by 2,227
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
Michot, J. M., Bigenwald, C., Champiat, S., Collins, M., Carbonnel, F., Postel-Vinay, S., Berdelou, A., Varga, A., Bahleda, R., Hollebecque, A., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.11.016 · Cited by 2,127
Acetaminophen‐induced acute liver failure
Larson, A. M., Polson, J., Fontana, R. J., Davern, T. J., Lalani, E., Hynan, L. S., REISCH, J. S., Schiødt, F. V., Ostapowicz, G., Shakil, A. O., et al. (2005) · Hepatology · doi:10.1002/hep.20948 · Cited by 1,913
Simplified criteria for the diagnosis of autoimmune hepatitis
Hennes, E. M., Zeniya, M., Czaja, A. J., Parés, A., Dalekos, G. N., Krawitt, E. L., Bittencourt, P. L., Porta, G., Boberg, K. M., Hofer, H., et al. (2008) · Hepatology · doi:10.1002/hep.22322 · Cited by 1,901
Flagged first, then by citations
5 of the 371 references couldn’t be matched to a known paper.
Research works printed but not linked: 5
- Nicoletti, 2017, Genome-wide association study (GWAS) to identify genetic risk factors that increase susceptibility to antituberculosis drug-induced liver injury (ATDILI) [Abstract], Hepatology, 66, A-25
- Lim, 2008, Association of HLA-B*1502 allele and carbamazepine-induced severe adverse cutaneous drug reaction among Asians, a review, Neurol Asia, 13, 15
- US Food & Drug Administration, 2017, Drugs
- Sanjuan-Jimenez, 2017, Prevalence of hepatitis E markers in Spanish patients with suspected drug-induced liver injury [abstract], Hepatology, 66, 423A
- Fernández-Castañer, 2008, An analysis of the causes, characteristics, and consequences of reexposure to a drug or compound responsible for a hepatotoxicity event, Rev Esp Enfermedades Dig, 100, 278
Cited by
Sorted by citations
Items 1,201–1,278 of 1,278
Wei, Y., Yao, M., Zhang, M., Liu, S., Yang, D., Ma, Z., Wu, H., Zhao, J., & Lu, F. (2026) · Clinics · doi:10.1016/j.clinsp.2026.101112
Tao, Y., Zhou, J., Wang, Y., Mao, Y., Lei, X., & Chen, E. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1871275
Serras, A. S., Camões, S. P., Rodrigues, J. S., Vej-Nielsen, J. M., Vitorino, R. M. P., Korkmaz, B., Cakan-Akdogan, G., & Miranda, J. P. (2026) · Toxicology Letters · doi:10.1016/j.toxlet.2026.112526
Dose-Response Assessment of Semaglutide: High-Dose-Induced Hepatotoxicity in Male Albino Rats
Sakr, F. N., & Lateff, N. I. (2026) · AMPLITUDO Journal of Science & Technology Innovation · doi:10.56566/amplitudo.v5i2.616
Lavon, O., & Salameh, M. (2026) · Clinical Case Reports · doi:10.1002/ccr3.73430
Vorasidenib-Induced Acute Liver Injury
Lau, E. A., Braxton, D. R., Autran, D., Chen, F., Haffner, A., Hu, J. L., Peters, K. B., & Fong, T. (2026) · Digestive Diseases and Sciences · doi:10.1007/s10620-026-10244-w
Taha, H. M., Khalifa, B. H., Hassan, M. Y., & Taha, K. H. (2026) · Case Reports in Hepatology · doi:10.1155/crhe/2519455
Acute Liver Failure in an Adolescent Following Use of the Synthetic REV‐ERB Agonist SR9009
Shaheen, S. S. B., Liu, W. J. P., Cooper, C. L., & Wu, M. Y. (2026) · Case Reports in Hepatology · doi:10.1155/crhe/9926772
Wang, H., Zheng, S., Hua, C., Feng, W., Liu, Z., Sun, Y., & Li, M. (2026) · Chemistry & Biodiversity · doi:10.1002/cbdv.71719
Ismihari, P. C., Novida, H., & Ekacitta, A. W. (2026) · Adolescencia e Saude · doi:10.67440/ahj.vi.2146
Wei, M., He, J., Zhang, Y., Chen, H., Wang, X., Liu, M., Chang, J., Fan, C., Jiang, H., & Shao, Y. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s608177
Liu, C., Luo, D., & Lin, R. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1956601
Chen, X., Zhao, X., Li, M., Ni, C., Wang, Y., Hu, Y., Han, X., & Xia, Z. (2026) · Clinical Therapeutics · doi:10.1016/j.clinthera.2026.08.018
Sachithanandam, S. V., Somashekar, N., & Dev, A. (2026) · Annals of African Medicine · doi:10.4103/aam.aam_878_26
Serras, A. S., Camões, S. P., Vitorino, R. M. P., & Miranda, J. P. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1819323
Slepov, I. K., Kopylov, E. D., Blagodatskikh, K. А., Gladysheva, N. P., Melchenko, D., Mirzaev, K. B., Sychev, D. A., & Deev, R. V. (2026) · Biomedicines · doi:10.3390/biomedicines14102162
Luglio, C. V., Ciaula, A. D., Sozzi, S., Conforti, C., Bitonto, G., & Portincasa, P. (2026) · Journal of Gastrointestinal and Liver Diseases · doi:10.15403/jgld-7570
Ogasawara, N. (2026) · Journal of Gastrointestinal and Liver Diseases · doi:10.15403/jgld-7489
Residual risk after SVR in advanced hepatitis C fibrosis: five-year real-world outcomes
Lima, R., Gomes, M. R., Maçano, R., Fagundes, C., & Mota, M. (2026) · Journal of Gastrointestinal and Liver Diseases · doi:10.15403/jgld-6949
Gastric cracked and cobblestone-like mucosa associated with long-term proton pump inhibitor use
Hokama, A., Tomiyama, R., & Hokama, A. (2026) · Journal of Gastrointestinal and Liver Diseases · doi:10.15403/jgld-6891
The “India ink sign” in the liver: chemical shift imaging findings in hepatic angiomyolipoma
Obara, J., Tamura, A., & YOSHIOKA, K. (2026) · Journal of Gastrointestinal and Liver Diseases · doi:10.15403/jgld-6979
Rare endogenous hepatic penetrating injury
Chen, Y., & Weng, W. (2026) · Journal of Gastrointestinal and Liver Diseases · doi:10.15403/jgld-6684
Abdulrahman, I., Rogojan, L., Albu, A., & Dumitrascu, D. L. (2026) · Journal of Gastrointestinal and Liver Diseases · doi:10.15403/jgld-6892
Chen, J., Dong, L., Yang, S., Wang, R., & Qi, X. (2026) · Journal of Gastrointestinal and Liver Diseases · doi:10.15403/jgld-6722
Chen, Y., & Lin, Q. (2026) · Journal of Gastrointestinal and Liver Diseases · doi:10.15403/jgld-7564
Arenas, Á., Ruedi, D., Walsen, G., & Patricio Ibáñez, L. (2026) · Journal of Gastrointestinal and Liver Diseases · doi:10.15403/jgld-6950
Kumar, V., Modi, H., Råberg, L., Rostami, L. D., Rosenholm, J. M., Carl-Eric, W., Stubelius, A., Goyal, R., & Bansal, K. K. (2026) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2026.127472
Kucharczyk, S., Sarek, F., Józwik, K., Rak, Z., Ignatowska, Z., Wielogórska, A. M., Kamecki, A., & Dzień, K. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(51).2026.6351
Li, X.-J., Zhang, N., Zhang, Q., Chen, R., & Yu, G. (2026) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-026-05686-z
Li, E.-C., Long, J., Yu, T., Qian, S., Qiu, F.-N., Liu, C.-L., Jiang, Y., & Li, H. (2026) · Food and Chemical Toxicology · doi:10.1016/j.fct.2026.116413
Association between β-lactam concentration and liver injury in critically ill patients
Farinella, A., Montanaro, F., Salvagno, M., Scaramuzzo, G., Volta, C. A., Spadaro, S., Cunha, A., Zorzi, S., Hites, M., Taccone, F. S., et al. (2026) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2026.108023
Thuy, P. T., Hoàng, T. T., Ha, N. T. T., Duc, D. M., Nguyen, H. A., Nguyen, T. T. H., Nguyen, N. T., Phuong, P. T., & Vu, G. V. (2026) · Respiratory Medicine Case Reports · doi:10.1016/j.rmcr.2026.102522
Fonseka, C. L., Chandrasiri, A., Gunawardhana, P. S., Sinhabahu, T., Jayasundara, D., Abusalem, L., Uluwattage, W. M., Gunasekara, C. A., Kappagoda, C., Warnasekara, J. N., et al. (2026) · SSRN Electronic Journal · doi:10.2139/ssrn.7543716
Case Report of Mixed Liver Injury Following Five Days Exposure to Cefepime in Young Adults
Widyati, W., Harijono, P., & Gunady Wibowo, R. (2026) · Pharmaceutical Sciences and Research · doi:10.7454/psr.v13i1.1469
Gastrobook: manual clínico de gastroenterología pediátrica
Carrillo, M. M. H., Rey, A. P., Domínguez, A. M. C., Acosta, A., Vásquez, C., Moreno, C. A., Velasco‐Suárez, D. A., Pulgarín, D. A., Hernández, D. P. S., Arce, I. F., et al. (2026) · Repositorio Institucional Universidad El Bosque
Srivarasat, S. (2026) · Phaholpolpayuhasena Hospital Journal
เกษรา, น. (2024) · Journal of Thai Traditional and Alternative Medicine
Role of serum liver markers and elastography in liver fibrosis evaluation depending on body weight
Prokopchuk, O. V., Hospodarskyy, I., Kozak, O., Gavryliuk, N., & Danchak, S. V. (2023) · Romanian Journal of Diabetes Nutrition and Metabolic Diseases
Idiosyncratic Drug-induced Liver Injury: A Diagnosis Beyond Simplicity
Shan, L. H., Terpari, T., & Sulaiman, W. (2023) · Asian Journal of Medicine & Health Sciences
Šimičević, L., Ganoci, L., Karačić, E., Božina, T., Pećin, I., Trkulja, V., & Božina, N. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1840055
Haddad, H., Benamor, M. L., Bekkar, Y., Boudebia, O., Nacer, S. N., Lanez, E., Adaika, A., Abdelhameed, T., Bechki, L., Lanez, T., et al. (2026) · Chemistry & Biodiversity · doi:10.1002/cbdv.71793
Histopathological Patterns in Drug-Induced Liver Injury
Özcan, T. B. (2026) · Balıkesır Health Sciences Journal · doi:10.53424/balikesirsbd.1947986
Chon, H. Y., Yun, H.-R., Jung, D. H., Lim, J., Gwon, S. H., Son, N., Youn, Y. H., & Huh, C. W. (2026) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2026.09.045
Post-hepatectomy Liver Failure
Carney, P. R., Schwartz, P. B., & Zafar, S. N. (2026) · Springer eBooks · doi:10.1007/978-3-032-28601-7_13
Gao, Z., Wang, S., Qiu, D., Hao, H., & Li, M. (2026) · Research Square · doi:10.21203/rs.3.rs-11115811/v1
Cardio-hepatic injury phenotypes and short-term outcomes in acute decompensated heart failure
Marcus, G., Maymon, S. L., Minha, I., Kalmanovich, E., Moravsky, G., Fuchs, S., Minha, S., & Grupper, A. (2026) · Clinical Research in Cardiology · doi:10.1007/s00392-026-03043-w
Sarswat, D., Quamuddin, M., Nimesh, S., Pandey, A., Anand, A., & Mandal, R. K. (2026) · Journal of Pharmaceutical Research Science & Technology · doi:10.31531/jprst.1000213
Shpati, A., Kamberi, A., Alushi, A., Saraci, N., Stela, P., Halimi, E., & Alushi, A. (2026) · Journal of Dentistry and Multidisciplinary Sciences · doi:10.3934/jdms.2026009
Mishra, K., Saxon, S., & Lynch, K. D. (2026) · BMJ Case Reports · doi:10.1136/bcr-2026-274700
Das, S., Singh, N., & Yadav, A. (2026) · Journal of Diabetes Metabolism and Endocrinology · doi:10.61336/jdme.0704.12
Ren, J., Yu, W., & Dai, Y. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1977830
Immune-mediated hepatitis. A literature review
Орлова, Р. В., Itkin, I. M., Иванова, А. К., & Kutcher, K. K. (2026) · Clinical Case in Oncology · doi:10.62546/3034-1477-2026-4-1-21-39
Adolf, J., & Enev, G. (2026) · Drug Testing and Analysis · doi:10.1002/dta.70174
Противоопухолевые ЛС и лекарственно-индуцированные поражения печени с холестазом
П., П. А., & Д., О. О. (n.d.) · CyberLeninK (CyberLeninka)
Павлович, П. А., Дмитриевна, О. О., Владимировна, Г. О., Витальевна, Ф. А., & Евгеньевна, П. Е. (n.d.) · CyberLeninK (CyberLeninka)
Лекарственные поражения печени в практике врача первичного звена (обзор клинических рекомендаций)
Д., О. О., В., Б. Е., Ф., П. Г., & Е., П. Е. (n.d.) · CyberLeninK (CyberLeninka)
Какое НПВС выбрать при болевом синдроме у полиморбидных пациентов?
Павлович, П. А. (n.d.) · CyberLeninK (CyberLeninka)
Casoliva, E. O., Montero, A. J. A., Carvalho, A. D., Morer, S. M., & Arvaniti, P. (2026) · Case Reports in Hepatology · doi:10.1155/crhe/1078239
Garrido‐Rodríguez, V., Remesal-Doblado, Á., García‐Cortés, M., Niu, H., Cárdenas-Quesada, J., Pinazo-Bandera, J. M., Toro-Ortiz, J. P., Pérez-López, E., Moreno‐González, R., Bonilla‐Toyos, E., et al. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1963613
Self-citationEffects of Conjugation Strategy on the Anticancer Activity and Selectivity of Melittin Bioconjugates
Nunes, L. O. C., Aragão, Á. F. L., Salvador, L. C., Fuentes, D. L. P., Navegante, G., Baracat, P. V. D. O., Stringhetta, G. R., de Moraes, R. O., Santiago, P. S., Oliveira, R. J. D. S., et al. (2026) · Protein and Peptide Letters · doi:10.1016/j.ppl.2026.10.004
Zhang, H., Zhao, P., Huang, H., & Zeng, Y. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.2003438
Acute-on-chronic liver failure: A global multisociety consensus on definitions
European Association for the Study of the Liver (EASL), American Association for the Study of Liver Diseases (AASLD), Asia-Pacific Association for the Study of the Liver (APASL), Latin American Association for the Study of the Liver (ALEH), & Society on Liver Disease in Africa (SOLDA) (2026) · Annals of Hepatology · doi:10.1016/j.aohep.2026.102453
Acute-on-chronic liver failure: a global multisociety consensus on definitions
Shawcross, D. L., Angeli, P., Shawcross, D. L., Moreno, C., Moreau, R., Wendon, J. A., Fernández, J., Trebicka, J., Angeli, P., Tonon, M., et al. (2026) · Hepatology International · doi:10.1007/s12072-026-11169-2
Acute-on-chronic liver failure: A global multisociety consensus on definitions
Angeli, P., Bajaj, J. S., Bahri, A. K., Castro, G. E., Choudhury, A. K., Debzi, N., Elkin, B. R., El-Kassas, M., Farias, A. Q., Fernández, J., et al. (2026) · Journal of Hepatology · doi:10.1016/j.jhep.2026.09.005
Acute-on-chronic liver failure: A global multisociety consensus on definitions
Society on Liver Disease in Africa (SOLDA) (2026) · Hepatology · doi:10.1097/hep.0000000000001891
Park, C., Oh, H., Jang, C., & Kim, T. H. (2026) · Antioxidants · doi:10.3390/antiox15111410
Yin, Y., & Zhang, G. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1971522
Elhassan, A., Ali, I., Mohamed, A.-B., & Mahgoub, A. (2026) · Cureus · doi:10.7759/cureus.119014
Beyond the Muscle–Kidney Paradigm: Liver–Muscle–Kidney Interactions in Rhabdomyolysis
Zhou, X., Deng, H.-B., Zhou, F., Tong, Z., & Gu, D. (2026) · Life · doi:10.3390/life16111852
Cecan, A. D., Cătoi, A. F., Țicolea, M., USATIUC, L., MITRE, A. O., FODOR, E. F., Ciobârcă, D., & MORAR, I.-I. (2026) · Bulletin of University of Agricultural Sciences and Veterinary Medicine Cluj-Napoca Food Science and Technology · doi:10.15835/buasvmcn-fst:2026.0053
Idiosyncratic Drug-Induced Liver Injury
Chalasani, N., Ghabril, M., & Vuppalanchi, R. (2026) · JAMA · doi:10.1001/jama.2026.16370
Miyata, A., Imai, S., Tsuchiya, M., Kizaki, H., & Hori, S. (2026) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b25-00724
Medication burden and FIB-4-defined risk classification in older adults: a real-world study
Koç, Z. (2026) · The Egyptian Journal of Internal Medicine · doi:10.1186/s43162-026-00759-z
Yang, X., Liu, Y., & Jingying, C. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1887345
Drug-induced liver injury: a comprehensive review
Hosack, T., Damry, D., & Biswas, S. (2023) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848231163410 · Cited by 214
Metadata
- Authors
- Andrade, R. J., Aithal, G. P., Björnsson, E. S., Kaplowitz, N., Kullak-Ublick, G. A., Larrey, D., & Karlsen, T. H.
- ORCID
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2019-06
- Volume
- 70
- Issue
- 6
- Pages
- 1222-1261
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W2924328881
- Semantic Scholar
- 6d774d1c570eef200451a1e8a8f5655c367a4eaf
- Cited by
- 1,276
- References
- 371
- Citations by year
- 2026: 243 · 2025: 211 · 2024: 175 · 2023: 159 · 2022: 158 · 2021: 184 · 2020: 117 · 2019: 27
- FWCI
- 78.91
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Hepatology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- European Cooperation in Science & Technology
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- drug-induced liver injury, idiosyncratic drug-induced liver injury, hepatotoxicity, acute liver failure, risk factors, diagnosis, risk minimization
- MeSH terms
- Adult, Aged, Fatty Liver, Female, Histocompatibility Testing, Humans, Liver Neoplasms, Male, Middle Aged, Mitochondria, Risk Factors, Chemical and Drug Induced Liver Injury
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
